Pharmacological manipulation of D1-dopamine receptor function in schizophrenia

Neuropsychopharmacology

Volumn 21, Issue 6, 1999, Pages S181-S188

  Sedvall, Göran C ^a   Karlsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autoradiography; D1 receptor; D2 receptor; Dopamine; Positron emission tomography (PET); Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 5 (7 BENZOFURANYL) 7 HYDROXY 3 METHYL 2,3,4,5 TETRA HYDRO 1H 3 BENZAZEPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; ECOPIPAM; MELPERONE; RACLOPRIDE; RITANSERIN; SULPIRIDE; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; DOPAMINE RECEPTOR BLOCKING; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0032794018     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00104-9     Document Type: Article

References (55)

1. Brene S, Hall H, Lindefors N, Karlsson P, Halldin C, Sedvall G (1995): Distribution of messenger RNAs for Dj-dopamine receptors and DARP-32 in striatum and cerebral cortex of the cynomolgus monkey: Relationship toDj dopamine receptors. Neuroscience 67:37-48
2. Burt DR, Creese I, Snyder SH (1977): Antischizophrenic drugs: Chronic treatment elevated dopamine receptorbinding in brain. Science 196:326-328
3. Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett AJ (1988): Pharmacological profile of sCh39166: A dopamine D1 selective benzonaphthazepinewith potential antipsychotic activity. J PharmacolExpTher 247:1093-1102
4. Clow A, Theodorou A, Jenner P (1980): Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration. Eur J Pharmacol63:135-144
5. Creese I, Burt DR, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potenciesof antischizophrenic drugs. Science 192:481-483
6. Farde L, Halldin C, Stone-Elander S, Sedvall G (1987): PET analysis of human dopamine receptor subtypes using11C-SCH 23390 and11C-raclopride. Psychopharmacol-ogy 92:278-284
7. Farde L, Nordström A-L, Nyberg S, Halldin C, Sedvall G (1994): Dj-, D2- and 5-HT2-receptor occupancy in cloza-pine-treated patients. J ClinPsychiat 55:67-69
8. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992): Positron emission tomographic analysis of central D1and D2dopamine receptor occupancyin patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch GenPsychiat 49:538-544
9. Farde L, Wiesel F-A, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988): An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptoroccupancy by PET. Psychopharmacology 94:1-7
10. Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordström A-L, Hall H, Sedvall G (1990): D2dopamine receptors inneuroleptic-naive schizophrenic patients. A positronemission tomography study with [uC]raclopride. ArchGen Psychiat 47:213-219
11. Goldman-Rakic P (1994): Cerebral cortical mechanisms in schizophrenia. Neuropsychopharmacology 10:225-275
12. Goldman-Rakic PS, Lidow MS, Gallager DW (1990): Overlap of dopaminergic, adrenergic, and serotonergic receptorsand complementarity of their subtypes in primate pre-frontal cortex. J Neurosci 10:2125-2138
13. Hall H, Farde L, Sedvall G (1988): Human dopamine receptor subtypes—In vitro binding analysis using3H-SCH 23390 and3H-raclopride. J Neural Transm 73:7-21
14. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G (1999): Visualization ofthe dopamine transporter in the human brain postmor-tem with the new selective ligand [125I]PE2I. Neuroim-age 9:108-116
15. Hall H, Halldin C, Sedvall G (1993): Binding of [3H]SCH 39166 to human post mortem brain tissue. PharmacolToxicol 72:152-158
16. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994): Distribution of D2- and D2-dopamine receptors, and dopamine and its metabolites in the human brain.Neuropsychopharmacology 11:245-256
17. Halldin C, Farde L, Barnett A, Sedvall G (1991): Synthesis of carbon-11 labeled SCH 39166, a new selective dopamineD-1 receptor ligand, and preliminary PET investiga-tions. Int J RadiatApplInstrum 42:451-455
18. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sand-ell J, Sedvall G, Farde L (1998): Carbon-11-NNC 112: A radioligand for PET examination of striatal and neocor-ticalDj-dopamine receptors. J Nucl Med 39:2061-2068
19. Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Gron-vald F, Swahn CG, Hall H, Sedvall G (1993): [UC]NNC 687 and [UC]NNC 756, dopamine D-1 receptor ligands.Preparation, autoradiography, and PET investigation inmonkey.Nucl Med Biol 20:945-953
20. Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth KJ, Längström B, Sedvall G (1986): Preparation ofuC-labeled SCH 23390 for the in vivo study of dopamine D-1 recep-tors using positron emission tomography. Int J RadiatApplInstrum 37:1039-1043
21. Härnryd C, Bjerkenstedt L, Björk K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel F-A, Wik G, Äberg-Wistedt A(1984): Clinical evaluation of sulpiride in schizophrenicpatients-A double-blind comparison with chlorprom-azine. ActaPsychiatScand 311:7-30
22. Härnryd C, Bjerkenstedt L, Gullberg B (1989): A clinical comparison of melperone and placebo in schizophrenicwomen on a milieu therapeutic ward. ActaPsychiatScand 352:40-47
23. Hess EJ, Bracha HS, Kleinman JE, Creese I (1987): Dopamine receptor subtype imbalance in schizophrenia. Life Sci40:1487-1497
24. Hietala J, Syvälahti E, Vuorio K, Nägren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, WegeliusU (1994): Striatal D2dopamine receptor characteristicsin neuroleptic-naive schizophrenic patients studiedwith positron emission tomography. Arch Gen Psychiat51:116-123
25. Karlsson P, Sedvall G, Halldin C, Swahn CG, Farde L (1995a): Evaluation of SCH 39166 as PET ligand for central D1dopamine receptor binding and occupancy inman. Psychopharmacology 121:300-308
26. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel F-A (1995b): Lack of apparent antipsychotic effect of the Dj-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309-316
27. Lachowicz JE, Sibley DR (1997): Molecular characteristics of mammalian dopamine receptors. PharmacolToxicol81:105-113
28. Lidow MS, Goldman-Rakic PS (1994): A common action of clozapine, haloperidol, and remoxipride on D:- and D2-dopaminergic receptors in the primate cerebral cortex.Proc Nat AcadSci USA 91:4353-4356
29. Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P (1991): Distribution of dopaminergic receptors in theprimate cerebral cortex: Quantitative, audioradio-graphic analysis using [3H]raclopride, [3H]spiperone, and [3H]SCH23390. Neuroscience 40:657-671
30. Lieberman JA, Kane JM, Alvir J (1987): Provocative tests with psychostimulant drugs in schizophrenia. Psycho-pharmacology 91:415-433
31. Lynch MR (1992): Schizophrenia and the D1 receptor: focus on negative symptoms. Prog NeuropsychopharmacolBiol Psychiat 16:797-832
32. Mackay AVP, Bird E, Spokes EG (1980): Dopamine receptors and schizophrenia: Drug effect or illness? Lancet 2:915-916
33. McQuade RD, Ford D, Duffy RA, Chipkin RE, Iorio L, Barnett A (1988): Serotonergic component of SCH23390: In vitro and in vivo binding analyses. Life Sci 43:1861-1869
34. Nielsen EB, Andersen PH (1992): Dopamine receptor occu-pancy in vivo: Behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1receptor antagonists. Eur J Pharmacol 219:35-44
35. Nordström A-L, Farde L, Eriksson L, Halldin C (1995): No elevated D2dopamine receptors in neuroleptic-naiveschizophrenic patients revealed by positron emissiontomography and [nC]N-methylspiperone. Psychiat Res61:67-83
36. Nybäck H, Sedvall G (1968): Effect of chlorpromazine on accumulation and disappearance of catecholaminesformed from tyrosine-C14in brain. J PharmacolExpTher 162:294-301
37. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997): Decreased prefrontaldopamine D1 receptors in schizophrenia revealed byPET. Nature 385:634-636
38. Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ (1978): Increased dopamine-receptor sensitivity inschizophrenia. Lancet 2:223-226
39. Owen F, Cross AJ, Waddington JL (1980): Dopamine-mediated behavior and 3H-spiperone binding to striatal membranes in rats after 9 months’ haloperidol administration. Life Sci 26:55-59
40. Rappaport MS, Sealfon SC, Prikhozhan A, Huntley GW, Morrison JH (1993): Heterogeneous distribution of D1, D2, and D5receptor mRNAs in monkey striatum. Brain Res 616:242-250
41. Sedvall GC (1996): Neurobiological correlates of acute neu-roleptic treatment. Int Clin Psychopharmacol 11:41-46
42. Sedvall GC, Farde L (1995): Chemical brain anatomy in schizophrenia. Lancet 346:743-749
43. Sedvall GC, Farde L, Barnett A, Hall H, Halldin C (1991):nC-SCH 39166, a selective ligand for visualization ofdopamine-D1receptor binding in the monkey brainusing PET. Psychopharmacology 103:150-153
44. Sedvall GC, Farde L, Nybäck H, Pauli S, Persson A, Savic I, Wiesel FA (1990): Recent advances in psychiatric brainimaging. ActaRadiolSuppl 374:113-115
45. Sedvall GC, Farde L, Persson A, Wiesel FA (1986): Imaging of neurotransmitter receptors in the living human brain.Arch Gen Psychiat 43:995-1005
46. Sedvall GC, Pauli S, Karlsson P, Farde L, Nordström AL, Nyberg S, Halldin C (1995): PET imaging of neurorecep-tors in schizophrenia. Eur Neuropsychopharmacol5:25-30
47. Seeman P (1980): Brain dopamine receptors. Pharmacol Rev 32:229-313
48. Seeman P, Lee T, Chau-Wong M, Wong K (1976): Antipsy-chotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
49. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtelotte WW (1984): Bimo-dal distribution of dopamine receptor densities in brainof schizophrenics. Science 225:728-730
50. Sunahara RK, Seeman P, Van Tol HHM, Niznik HB (1993): Dopamine receptors and antipsychotic drug response.Br J Psychiat 163:31-38
51. Taylor LA, Tedford CE, McQuade RD (1991): The binding of SCH 39166 and sCh 23390 to 5-HT1Creceptors in por-cine choroid plexus. Life Sci 49:1505-1511
52. Wiesel F-A, Farde L, Nordström A-L, Sedvall G (1990): Central D1- and D2-receptor occupancy during antipsy-chotic drug treatment. Prog Neuropsychopharmacol Biol Psychiat 14:759-767
53. Wiesel F-A, Nordström A-L, Farde L, Eriksson B (1994): An open clinical and biochemical study of ritanserin inacute patients with schizophrenia. Psychopharmacology 114:31-38
54. Wong DF, Wagner HN Jr., Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, RavertHT, Wilson AA, Toung JKT, Malat J, Williams FA, O’Touma LA, Snyder SH, Kuhar MJ, Gjedde A (1986):Positron emission tomography reveals elevated D2-dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563
55. Yamamoto T, Kebabian JW (1989): [125I]SCH23982 binds to a serotonin receptor (and not to a D-1 dopamine receptor)in the rat choroid plexus. Biogen Amines 6:241-246